Medtronic (MDT) Competitors

Medtronic has higher revenue and earnings than Intuitive Surgical. Medtronic is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Intuitive Surgical has a net margin of 28.45% compared to Medtronic's net margin of 13.20%. Intuitive Surgical's return on equity of 16.91% beat Medtronic's return on equity.

Intuitive Surgical currently has a consensus target price of $509.02, suggesting a potential upside of 44.21%. Medtronic has a consensus target price of $98.83, suggesting a potential upside of 15.27%. Given Intuitive Surgical's higher possible upside, research analysts plainly believe Intuitive Surgical is more favorable than Medtronic.

83.6% of Intuitive Surgical shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.6% of Intuitive Surgical shares are held by insiders. Comparatively, 0.3% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Intuitive Surgical has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

In the previous week, Intuitive Surgical had 27 more articles in the media than Medtronic. MarketBeat recorded 55 mentions for Intuitive Surgical and 28 mentions for Medtronic. Medtronic's average media sentiment score of 1.07 beat Intuitive Surgical's score of 1.06 indicating that Medtronic is being referred to more favorably in the news media.

In the previous week, Abbott Laboratories had 30 more articles in the media than Medtronic. MarketBeat recorded 58 mentions for Abbott Laboratories and 28 mentions for Medtronic. Abbott Laboratories' average media sentiment score of 1.11 beat Medtronic's score of 1.07 indicating that Abbott Laboratories is being referred to more favorably in the media.

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 0.3% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Abbott Laboratories has higher revenue and earnings than Medtronic. Medtronic is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Medtronic has a net margin of 13.20% compared to Abbott Laboratories' net margin of 11.65%. Abbott Laboratories' return on equity of 17.69% beat Medtronic's return on equity.

Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.4%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.4%. Abbott Laboratories pays out 81.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medtronic pays out 77.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories has raised its dividend for 54 consecutive years and Medtronic has raised its dividend for 49 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and lower payout ratio.

Abbott Laboratories has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Abbott Laboratories currently has a consensus price target of $118.17, suggesting a potential upside of 11.67%. Medtronic has a consensus price target of $98.83, suggesting a potential upside of 15.27%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than Abbott Laboratories.

Boston Scientific currently has a consensus price target of $71.62, suggesting a potential upside of 55.96%. Medtronic has a consensus price target of $98.83, suggesting a potential upside of 15.27%. Given Boston Scientific's stronger consensus rating and higher probable upside, equities analysts clearly believe Boston Scientific is more favorable than Medtronic.

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Medtronic has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

In the previous week, Boston Scientific had 64 more articles in the media than Medtronic. MarketBeat recorded 92 mentions for Boston Scientific and 28 mentions for Medtronic. Medtronic's average media sentiment score of 1.07 beat Boston Scientific's score of 0.59 indicating that Medtronic is being referred to more favorably in the news media.

Boston Scientific has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Boston Scientific has a net margin of 17.50% compared to Medtronic's net margin of 13.20%. Boston Scientific's return on equity of 19.36% beat Medtronic's return on equity.

Johnson & Johnson has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Johnson & Johnson has higher revenue and earnings than Medtronic. Medtronic is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.1%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.4%. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Medtronic pays out 77.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has increased its dividend for 64 consecutive years and Medtronic has increased its dividend for 49 consecutive years.

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.3% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Johnson & Johnson had 94 more articles in the media than Medtronic. MarketBeat recorded 122 mentions for Johnson & Johnson and 28 mentions for Medtronic. Medtronic's average media sentiment score of 1.07 beat Johnson & Johnson's score of 0.87 indicating that Medtronic is being referred to more favorably in the news media.

Johnson & Johnson currently has a consensus price target of $266.39, indicating a potential upside of 4.12%. Medtronic has a consensus price target of $98.83, indicating a potential upside of 15.27%. Given Medtronic's higher probable upside, analysts clearly believe Medtronic is more favorable than Johnson & Johnson.

Johnson & Johnson has a net margin of 21.48% compared to Medtronic's net margin of 13.20%. Johnson & Johnson's return on equity of 32.42% beat Medtronic's return on equity.